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Angptl4 (Angiopoietin-like 4) is a circulating protein secreted
by white and brown adipose tissues and the liver. Structurally,
Angptl4 contains an N-terminal coiled-coil domain (CCD) con-
nected to aC-terminal fibrinogen-like domain (FLD) via a cleav-
able linker, and both full-length Angptl4 and its individual
domains circulate in thebloodstream.Angptl4 inhibits extracel-
lular lipoprotein lipase (LPL) activity and stimulates the lipoly-
sis of triacylglycerol stored by adipocytes in the white adipose
tissue (WAT). The former activity is furnished by the CCD, but
theAngptl4 domain responsible for stimulating adipocyte lipol-
ysis is unknown.We show here that the purified FLD of Angptl4
is sufficient to stimulate lipolysis in mouse primary adipocytes
and that increasing circulating FLD levels in mice through ade-
novirus-mediated overexpression (Ad-FLD) not only induces
WAT lipolysis in vivo but also reduces diet-induced obesity
without affecting LPL activity. Intriguingly, reduced adiposity
in Ad-FLD mice was associated with increased oxygen con-
sumption, fat utilization, and the expression of thermogenic
genes (Ucp1 and Ppargc1a) in subcutaneous WAT. Moreover,
Ad-FLD mice exhibited increased glucose tolerance. Chroni-
cally enhancing WAT lipolysis could produce ectopic steatosis
because of an overflow of lipids from the WAT to peripheral
tissues; however, this did not occur when Ad-FLD mice were
fed a high-fat diet. Rather, these mice had reductions in both
circulating triacylglycerol levels and the mRNA levels of lipo-
genic genes in the liver and skeletal muscle.We conclude that
separating the FLD from the CCD-mediated LPL-inhibitory
activity of full-length Angptl4 reveals lipolytic and thermo-
genic properties with therapeutic relevance to obesity and
diabetes.
Angptl4 (angiopoietin-like 4; also known as fasting-induced
adipose factor, FIAF) is a circulating protein expressed in and
secreted by white and brown adipose tissues (WAT and BAT,
respectively)4 and the liver (1–4). Angptl4 is a part of the eight-
member angiopoietin-like family of structurally related pro-
teins, and the human ANGPTL4 gene is highly conserved
amongmammals, sharing a 77% amino acid sequence similarity
with that ofmice (3, 5). Structurally, Angptl4 contains anN-ter-
minal coiled-coil domain (CCD) connected to a C-terminal
fibrinogen-like domain (FLD) via a cleavable linker (3, 6). Both
full-length and truncated forms of Angptl4 circulate in the
bloodstream, and the processing of Angptl4 may be tissue-de-
pendent: the liver secretes mainly truncated forms, whereas
WAT secretes mainly the full-length form (7, 9). The expres-
sion of Angptl4 can be induced by several stimuli, including
fasting, glucocorticoids, non-esterified fatty acids, thyroid hor-
mone, and relative hypoxia (7, 9–12).
The CCD of Angptl4 is responsible for the ability of Angptl4
to inhibit lipoprotein lipase (LPL) (13, 14), the enzyme respon-
sible for hydrolyzing circulating lipoprotein-associated triacyl-
glycerol (TG) to produce free fatty acids (FFAs) for uptake by
surrounding tissues. Adenoviral overexpression of full-length
human ANGPTL4 in mice causes severe hypertriglyceridemia
and hepatic steatosis, whereas mice lacking the gene encoding
Angptl4 (Angptl4/) have much lower plasma and liver TG
levels than WT controls (15). This hypolipidemic phenotype
correlates with human genetic data supporting a key role for
ANGPTL4 in maintaining plasma TG levels (16, 17).
Most notably, 3% of European Americans harbor a single
nucleotide polymorphism in which the glutamic acid at posi-
tion 40 of ANGPTL4, within the CCD, is replaced by a lysine
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(E40K), decreasing the ability of ANGPTL4 to inhibit LPL (16,
18, 19). Indeed, people expressing E40K have reduced plasma
levels of TG and LDL cholesterol and elevated levels of HDL-
cholesterol, although it is not associatedwith altered bodymass
index or adiposity.
The E40K mutation in ANGPTL4 was initially viewed as the
human equivalent of Angptl4/ mice; however, it is now
known that ANGPTL4 is a bifunctional protein that stimulates
adipocyte lipolysis in addition to inhibiting LPL activity (8, 20).
However, the domain of ANGPTL4 responsible for stimulating
adipocyte lipolysis is unknown. One possibility is that FLD
might carry out this function.
Prior studies showed that FLD binds 1, 3, and 5 integrins
(21–23); activates the integrin-dependent focal adhesion
kinase-Src–p21–activated kinase 1 cascade required for kerati-
nocyte migration (21); interacts with vitronectin and fibronec-
tin to induce the activation of integrin-dependent focal adhe-
sion kinase, 14-3-3 proteins, and PKC during wound healing
(24); and stimulates NADPH oxidase-dependent O2. produc-
tion to protect cancer cells from anoikis and apoptosis (23). By
contrast, the role of FLD in metabolism has not been explored.
We showed that purified ANGPTL4 directly induces adi-
pocyte lipolysis by increasing intracellular cAMP levels. More-
over, lipolysis induced by fasting or glucocorticoid treatment is
reduced inAngptl4/mice (8). Here, we show that the FLD of
Angptl4 alone stimulates adipocyte lipolysis through a mecha-
nism structurally distinct from that by which Angptl4 inhibits
LPL. We retained the pro-lipolytic activity of Angptl4 while
eliminating its LPL-inhibitory activity by using adenoviral
delivery to specifically increase circulating FLD levels in mice
(Ad-FLD). Remarkably, doing so increasesWAT lipolysis, low-
ers adiposity by increasing energy expenditure in conjunction
with beige thermogenesis, prevents ectopic tissue steatosis, and
improves glucose homeostasis under conditions of dietary
excess.
Results
The FLD of Angptl4 is sufficient to stimulate adipocyte lipolysis
Prior studies showed that the CCD of Angptl4 can inhibit
extracellular LPL activity (14). To determine whether the CCD
is required to stimulate intracellular TG hydrolysis in adi-
pocytes, we used adenovirus to express a FLAG-tagged mutant
form of human ANGPTL4, which retains both the signal
sequence needed for secretion and the intact FLD but which
lacks amino acids 38–165 of the CCD (Ad-FLD), in the livers of
adult mice (Fig. 1A). Controls included mice overexpressing
either FLAG-tagged human full-length ANGPTL4 (Ad-ANG-
PTL4) or LacZ (Ad-LacZ) (Fig. 1B). Immunoblot analysis of
plasma collected from mice 3 weeks after adenoviral injection
(anti-FLAG) confirmed the presence of FLAG-tagged FLD or
ANGPTL4 in the appropriate mice (the FLAG tag is located at
the C terminus in each case). Notably, full-length ANGPTL4 is
normally post-translationally cleaved into both CCD and FLD
Figure 1. FLD exerts effects on lipid homeostasis, in vivo and in vitro, that are distinct from those of full-length Angptl4. A, graphical depiction of the
Ad-ANGPTL4 and Ad-FLD constructs. B, top panel, schematic showing adenoviral strategy to generate Ad-ANGPTL4, Ad-FLD, and Ad-LacZmice. Bottom panel,
immunoblot using anti-FLAG M2 antibody (Sigma, 1:1000) and a corresponding ANTI-FLAG affinity gel showing increased FLD abundance in the plasma of
both Ad-ANGPTL4 and Ad-FLD mice (blot was cropped). C and D, plasma TG (C) and (D) FFA measurements showing that Ad-ANGPTL4 mice fed a standard
chow diet have increased levels of both TG and FFAs versus Ad-LacZ controls, whereas Ad-FLDmice have elevated FFA levels without concomitant hypertrig-
lyceridemia (n  5–6 mice/group for A–D; *, p  0.05 versus Ad-LacZ). E and F, glycerol release (E) and intracellular cAMP (F) levels measured from primary
mouse adipocytes treated for 1 h with purified ANGPTL4, FLD, or the E40K mutant form of ANGPTL4 showing that each stimulates adipocyte lipolysis with
similar potency (n 7 mice/group; *, p 0.05 versus PBS-treated controls).
ANGPTL4 fibrinogen-like domain and energy expenditure
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forms (7, 9), accounting for our seeing FLAG-detected proteins
from the plasmaofAd-FLDandAd-ANGPTL4mice running at
similar molecular weights (Fig. 1B). As expected, no signal was
detected in the plasma of Ad-LacZ mice (Fig. 1B). Plasma TG
levels were increased in Ad-ANGPTL4 mice (versus Ad-LacZ)
butwere not altered inAd-FLDmice, consistentwith the role of
CCD in LPL inhibition (Fig. 1C). Plasma FFA levels, on the
other hand, were markedly increased in both Ad-ANGPTL4
and Ad-FLD mice, suggesting that FLD alone is sufficient to
promote WAT lipolysis (Fig. 1D).
To directly test this, we treated isolated primary adipocytes
with 20 nM of either purified ANGPTL4 or FLD for 1 h. Both
ANGPTL4 and FLD treatments increased adipocyte glycerol
release (Fig. 1E), indicating enhanced lipolysis. Seeing that FLD
alone is sufficient to stimulate intracellular lipolysis by adi-
pocytes led us to predict that this ability would be retained by
the C-terminal E40Kmutant form of ANGPTL4, which cannot
properly inhibit LPL. Indeed, purified E40K ANGPTL4 also
stimulated glycerol release from primary adipocytes (Fig. 1E).
Moreover, ANGPTL4, FLD, and E40K treatment each signifi-
cantly increased cAMP levels in adipocytes, supporting the
concept that each stimulates a common pro-lipolytic pathway
(Fig. 1F). Together, these findings demonstrate that the FLD of
ANGPTL4 is sufficient to stimulate intracellular adipocyte
lipolysis.
Ad-FLDmice are protected from diet-induced obesity (DIO)
Given the ability of FLD to stimulate adipocyte lipolysis, we
usedAd-FLDandAd-LacZmice to determinewhether increas-
ing plasma FLD levels in mice would reduce adiposity. Immu-
noblot analysis of plasma collected from mice 10 days after
adenoviral injection (anti-FLAG) confirmed the presence of
FLAG-tagged FLD in the appropriate mice (Fig. 2A, left panel).
No signal was detected in the plasma of Ad-LacZmice (Fig. 2A,
left panel). To estimate the plasma concentration of exogenous
FLD expression in Ad-FLD mice, similar immunoblots were
performed on 20.5 ng of purified FLAG-FLDprotein run along-
side 3 l of plasma from Ad-FLD mice. By comparing the rela-
tive intensity of the bands produced by these immunoblots, we
calculated that the plasma samples from Ad-FLD mice con-
tained 2 ng/l, or 61.5 nM, of FLAG-FLD (Fig. 2A, right
panel). In accordance with this degree of FLD overexpression,
Ad-FLDmice fed aHFD gained less weight thanAd-LacZmice,
with a divergence beginning after 1 week on the diet (Fig. 2B),
despite having food intake similar to control (Fig. 2C).
Analyzing this protection against DIO revealed that Ad-FLD
mice fed a HFD have a pervasive reduction in body fat that
includes the inguinal and epididymalWAT (iWATand eWAT)
and BAT depots, which weighed 37, 46, and 36% less, respec-
tively, than those from Ad-LacZ mice (Fig. 2,D and E). By con-
trast, hepatic, cardiac, and gastrocnemius muscle weights were
similar between Ad-FLD and Ad-LacZ mice (Fig. 2E), indicat-
ing that increasing systemic FLD levels lowers body weight by
specifically reducing adiposity. This specificity was confirmed
by monitoring body composition (DEXA) 21 days after adeno-
viral injection; the lean mass of Ad-FLD mice was increased
compared with Ad-LacZ controls, whereas the fat mass of Ad-
FLD mice was reduced by 67% versus Ad-LacZ controls
(Fig. 2F).
Given that Ad-FLDmice had elevated plasma FFA levels and
unaffected plasma TG levels when fed a standard chow diet, we
hypothesized that we would see a similar pattern of dyslipi-
demia when Ad-FLD and Ad-LacZ mice were fed a HFD.
Indeed, plasma TG levels in the context of a HFD were not
different between Ad-FLD and Ad-LacZ mice, consistent with
the role of CCD in LPL inhibition (Fig. 3A). Moreover, plasma
FFA levels were elevated in Ad-FLD mice fed a HFD, just as
when the mice were fed a chow diet, further supporting that
FLD alone is sufficient to promote WAT lipolysis (Fig. 3B).
Wehypothesized that chronic, FLD-mediatedWAT lipolysis
enhances the flux of mobilized FFAs to ectopic tissues such as
the liver and skeletal muscle, where theymight be stored as TG,
resulting in tissue steatosis. However, we found surprisingly
that that the protection against DIO seen in the context of
increasing systemic FLD levels occurredwithout inducing non-
adipose tissue steatosis. Indeed, TG levels in the livers and skel-
etal muscle of Ad-FLD mice were 24 and 44% lower, respec-
tively, than in Ad-LacZ mice (Fig. 3C).
One possible mechanism for the lack of steatosis in Ad-FLD
mice fed a HFD is that these mice have enhanced fatty acid
oxidation (FAO) in non-adipose tissues. However, the mRNA
levels of genes involved in FAO were not different between
genotypes (data not shown). Another possibility is that Ad-FLD
mice fed a HFD have reduced TG synthesis, storage, or fat
uptake in the liver and skeletal muscle. Examining this possibil-
ity revealed that the mRNA levels of genes encoding proteins
involved in TG synthesis (e.g. Dgat2 (DGAT2), Lpin1 (Lipin-1),
and Agpat2 (AGPAT2)), transcriptional control of lipogenesis
(Srebf1 (SREBP-1c) and Mlxipl (ChREBP)), and fatty acid
uptake and synthesis (Cd36 (FAT/CD36) and Fasn (FAS)) are
on the whole markedly lower in the livers, gastrocnemius mus-
cles, and the iWATand eWATofAd-FLDmice versusAd-LacZ
controls (Fig. 3D). Thus, the potential impact of FLD-induced
WAT lipolysis on hepatic andmuscle steatosis may be offset by
the transcriptional down-regulation of fat synthesis and storage
programs in these tissues.
Ad-FLDmice have enhanced cold-inducible energy
expenditure
Beyond linking increased adipocyte lipolysis with decreased
adiposity in theWAT, we explored how Ad-FLDmice are pro-
tected from DIOmore mechanistically. To do so, we fed singly
housed Ad-FLD and Ad-LacZmice a HFD for 21 days and then
placed them into a comprehensive laboratory animal monitor-
ing system (CLAMS) to perform indirect calorimetry. Ad-FLD
mice fed a HFD had 9.9% higher oxygen consumption (VO2)
and 8.3% higher carbon dioxide production (VCO2) during the
dark period than did Ad-LacZ mice (Fig. 4, A–D). There were
no differences in VO2 or VCO2 between groups during the light
period. In accordance with these findings, the respiratory
exchange ratios (RERs) of Ad-FLD mice fed a HFD were
reduced versus control mice (Fig. 4E) and were present during
both the light period (6.8% reduction) and the dark period (1.8%
reduction). These results indicate that Ad-FLDmice rely more
on fat to fuel metabolic processes than do control mice and
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correspondwith the ability of FLD to induceWAT lipolysis and
raise plasma FFA levels. Overall, these results strongly support
the concept that increasing circulating FLD levels in mice
augments energy expenditure and thus lowers adiposity by
coordinately coupling enhancedWAT lipolysis to greater fat
utilization.
Figure 2. Increasing circulating levels of FLD in isolation limits DIO inmice. A, immunoblot (left panel) and quantification (right panel) of purified (20.5 ng)
FLAG-FLDproteins and plasma samples (3l) fromAd-LacZ andAd-FLDmice, using an anti-FLAGM2 antibody (Sigma, 1:1000). Plasmawas isolated fromboth
Ad-LacZ and Ad-FLDmice 10 days after infection. B and C, body weight curves (B) and average food intake values (C) for Ad-LacZ and Ad-FLDmice fed a HFD
for 3 weeks. D, representative images showing the reduction in BAT, iWAT, and eWAT masses induced by FLD overexpression in the context of a HFD. E,
quantification of C, as well as equivalent weight values for other tissues represented in percentage of body weight in Ad-LacZ and Ad-FLDmice fed HFD for 3
weeks. F, respective lean and fatmasses represented inpercentageof bodyweight in themicementioned above, as determinedbyDEXA, showing the specific
reduction in fat mass seen in Ad-FLD mice fed a HFD for 3 weeks. In all cases, n 6 mice/group; *, p 0.05 versus Ad-LacZ.
ANGPTL4 fibrinogen-like domain and energy expenditure
J. Biol. Chem. (2017) 292(39) 16122–16134 16125
 at U
niversity of California, Berkeley on Septem
ber 29, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ANGPTL4 fibrinogen-like domain and energy expenditure
16126 J. Biol. Chem. (2017) 292(39) 16122–16134
 at U
niversity of California, Berkeley on Septem
ber 29, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
After establishing the ability of FLD to stimulate energy
expenditure at room temperature (22–23 °C), which prior stud-
ies indicate is cold enough to stimulate reactive thermogenesis
inmice (25), we examined Ad-FLDmice at thermoneutrality to
eliminate any such thermogenic stress. Ad-FLD and Ad-LacZ
mice fed a HFD for 21 days were placed into a CLAMS main-
tained at 30 °C, and indirect calorimetry was performed. Inter-
estingly, measuring VO2 and VCO2 in this setting eliminated
the excess energy expenditure that had been seen in Ad-FLD
mice at room temperature (Fig. 5, A–D), indicating that FLD
drives energy expenditure in mice by potentiating their non-
shivering thermogenic response to cold. Notably, the tempera-
ture dependence of FLD-stimulated energy expenditure was
not reflective of its impact on fuel utilization; RER was 5.3%
lower in Ad-FLD (light period) even at thermoneutrality
(Fig. 5E).
Increasing systemic FLD levels induces beige conversion in the
WAT
To test whether the ability of FLD to enhance cold-inducible
energy expenditure in Ad-FLDmice results from the activation
of BAT or beige conversion within the iWAT, we isolated
iWATandBAT fromAd-LacZ andAd-FLDmice fed aHFD for
3 weeks. Oxygen consumption, which we monitored in each of
these tissues ex vivo, was increased 2.5-fold in the iWAT of
Ad-FLD mice (Fig. 6A) but was similar in the BAT of Ad-LacZ
and Ad-FLD mice (Fig. 6B). Similarly, the extracellular acidifi-
cation rate (ECAR), indicative of glucose utilization, was 2.9-
fold higher in the iWAT of Ad-FLD mice versus control (Fig.
6C) but was not altered in the BAT (Fig. 6D). Therefore,
increasing systemic FLD levels enhances cellular respiration
and increases glucose utilization specifically in the iWAT, high-
lighting the role of this specific fat depot in FLD stimulation of
systematic energy expenditure.
We also monitored oxygen consumption rate (OCR) and
ECAR in the iWAT and BAT of Ad-LacZ and Ad-FLD mice at
thermoneutrality. Again, although OCR and ECAR remained
elevated in the iWAT of Ad-FLD mice versus control, these
elevations were greatly diminished (46% for OCR and 43% for
ECAR) when compared with values taken at standard room
temperature (Fig. 6, A and C). These data support the temper-
ature-dependent nature by which increased systemic FLD lev-
els stimulate energy utilization in the iWAT. Notably, whereas
OCR values in the BAT were similar in Ad-FLD and Ad-LacZ
mice whether themice were housed at 23 or 30 °C, ECAR in the
BAT of Ad-FLDmice fell by 34% in response to thermoneutral-
ity (Fig. 6B and D).
Certain WAT depots contain so-called “beige” adipocytes
that can acquire a phenotype reminiscent of “brown” adi-
pocytes residing in the BAT when exposed to cold or certain
agents (26–29). Unlike white adipocytes, beige and brown adi-
pocytes dissipate energy as heat. That Ad-FLD mice have ele-
vated OCR in the iWAT, where beige precursor cells are prev-
alent (30), suggests that increasing systemic FLD levels induces
beige/brown conversion in the iWAT. Supporting this conten-
tion, we found that the mRNA levels of thermogenic genes
(Ppargc1a (a.k.a. Pgc1), Cidea and Ucp1), were significantly
elevated in iWATofAd-FLDmice housed at 23 °C (Fig. 6,E and
F, left panel).
We also assessed tissue levels of uncoupling protein-1
(Ucp1), which is encoded by the Ucp1 gene and is indicative of
thermogenic activation in beige and brown adipocytes.We saw
that Ad-FLDmice had a striking increase over Ad-LacZmice in
the expression Ucp1 in the iWAT, but not the eWAT or BAT
(Fig. 6F, right panel). Taken together, our data indicate that
systemically increasing FLD levels promotes beige/brown con-
version and thermogenic activation within the iWAT and
strongly suggests that this mechanism is chiefly responsible for
driving energy expenditure in Ad-FLD mice.
Ad-FLDmice have improved glucose intolerance under
conditions promoting DIO
Reduced adiposity and increased energy expenditure are fre-
quently accompanied by improved glucose homeostasis. We
thus performed glucose tolerance tests on Ad-LacZ and Ad-
FLD mice fed a HFD for 3 weeks. Indeed, Ad-FLD mice under
these dietary circumstances have markedly improved glucose
tolerance, despite also having an 50% reduction in fasting
plasma insulin levels (Fig. 7,A and B). Gene expression analysis
showed that themRNA levels of genes encoding gluconeogenic
enzymes, such as phosphoenolpyruvate carboxykinase (Pck1)
and glucose-6-phosphatase catalytic subunit (G6pc), were
lower in livers of Ad-FLD mice than those of Ad-LacZ mice
(Fig. 7C), suggesting that reduced hepatic glucose production
contributes to the improved glucose tolerance seen in Ad-FLD
mice fed a HFD.
Discussion
Angptl4 mobilizes FFAs from the WAT by promoting adi-
pocyte lipolysis and limits uptake of circulating TG into the
WAT by inhibiting extracellular LPL activity (31). The N-ter-
minal CCD of Angptl4 is responsible for its ability to inhibit
LPL. We show here that the C-terminal FLD of Angptl4 is
responsible for stimulating adipocyte lipolysis, a finding that
has important physiological and pharmacological implications
for obesity and type 2 diabetes.
Angptl4 circulates in full-length and truncated forms,
including its CCD and FLD, respectively. Therefore, stimuli
such as fasting and glucocorticoids by definition increase circu-
lating levels of full-length Angptl4, together with its individual
CCD and FLD components, which then coordinately regulate
lipid homeostasis. Supporting this concept, we noted that the
FLAG-tagged proteins circulating in Ad-ANGPTL4 and Ad-
FLDmice were of a similar size. This indicates either that most,
Figure 3. Increasing circulating levels of FLD reduces indicators of fat uptake, synthesis, and storage. A and B, measurements of plasma TG (A) and
plasma FFA (B) concentrations showing that Ad-FLD mice fed a HFD have elevated FFA levels versus Ad-LacZ controls without concomitant hypertriglyceri-
demia (n 4–5mice/group; *, p 0.05 versus Ad-LacZ). C, liver and skeletal muscle (gastrocnemius) TG content showing reduced values for Ad-FLDmice fed
a HFD in both tissues (n  6 mice/group; *, p  0.05 versus Ad-LacZ). D, qPCR data showing markedly lower mRNA levels of genes involved in glycerolipid
synthesis, FFAuptake, lipogenesis, and the transcriptional control of theseprocesses, in the iWAT, eWAT, livers, and skeletalmuscles (gastrocnemius) ofAd-FLD
mice versus Ad-LacZ controls (n 5–6 mice/group; *, p 0.05 versus control).
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if not all, circulating Angptl4 is cleaved into CCD and FLD
components or that the ability of Ad-Angptl4 mice to secrete
full-length protein hadwaned by the timewe drew plasma sam-
ples, leaving only long-lived truncated forms in the circulation.
Although artificially increasing circulating levels of full-
lengthAngptl4 should reduce adiposity, this processwould also
be expected to produce marked hypertriglyceridemia and
potentially widespread non-adipose tissue steatosis. On the
other hand, if FLD levels could be systemically increased with-
out concomitantly increasing CCD levels, then it might be pos-
sible tomitigate DIOwithout risking hyperlipidemia or ectopic
steatosis. However, the FLD of Angptl4 had not been studied in
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measured at 23 °C over a 24-h period in Ad-LacZ and Ad-FLDmice (n 6mice/group) fed a HFD for 3 weeks. B, average VO2 during the light and dark periods
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isolation, and its impact on lipid, energy, and glucose homeo-
stasis had not been explored. We used an adenoviral system to
overexpress FLD in the livers of mice, thusmarkedly increasing
its levels in the circulation. Remarkably, this strategy reduced
adiposity in mice without raising circulating TG levels.
Although a previous report showed that injecting FLD into the
brains ofmice reduces food intake (32), we did not observe such
a phenotype, suggesting that circulating FLDmay not cross the
blood–brain barrier. We estimated that the plasma levels of
FLD achieved in our overexpressionmodel was61.5 nMwhen
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Figure 5. Ad-FLDmice fed a HFD at thermoneutrality do not have enhanced energy expenditure. A, whole-body oxygen consumption (VO2) measured
at 30 °C over a 24-h period in Ad-LacZ andAd-FLDmice (n 6mice/group) fed aHFD for 3weeks. B, average VO2 during the light and dark periods for the data
in A. C, carbon dioxide production (VCO2) measured over 24 h from the mice in A. D, average VCO2 during light and dark periods for the data in C. E, RERs
measured at 30 °C and during light and dark periods from the mice in A. *, p 0.05 versus Ad-LacZ in all cases.
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Figure6. Increasing circulating levels of FLD in isolation inducesbeige/brownconversion inmice fedaHFD.A, OCRmeasured from iWAT samples taken
from Ad-LacZ and Ad-FLDmice fed a HFD for 3 weeks. B–D, OCRmeasured from the BAT (B), ECARmeasured from the iWAT (C), and ECARmeasured from the
BAT (D) of the samemice as in A. E, qPCR data showingmarkedly increasedmRNA levels of thermogenic genes involved in the iWAT of Ad-FLDmice fed a HFD
as in A. F, qPCR data showingmarkedly increasedmRNA levels of Ucp1 (left panel) and representative immunoblots (right panel; blots are cropped) showing a
sharp induction of Ucp1 (U6382; Sigma) in the iWAT of Ad-FLDmice versus Lac-Zmice fed a HFD as in A. GAPDH used as internal control (ab9483; Abcam) (n
5–6 mice/group; *, p 0.05 versus Ad-LacZ for all experiments).
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measured 10 days following adenoviral infection. Interestingly,
we previously estimated that plasma levels of intact full-
length Angptl4 reach to 11.6 nM after a 24-h fast (8). Thus,
circulating FLD levels in our overexpressionmodel may be at
least 5.3 times higher than what might be achieved by pro-
longed fasting.
On the other hand, there are two factors to consider when
evaluating FLD levels in the blood of Ad-FLD mice. First, the
ELISA we performed previously used antibodies recognizing
the CCD, rather than FLD, of Angptl4. Thus, we could have
underestimated the plasma levels of FLD in our analysis of
full-length Angptl4 levels. It is also possible that peak circu-
lating FLD levels in Ad-FLD mice are higher than 61.5 nM,
based on the fact that peak adenovirus-mediated FLD
expression could be either prior to or after the 10-day postin-
fection time point when our measurements were made.
Future experiments should utilize the administration of
purified FLD proteins to confirm the exact concentrations of
plasma FLD needed to produce the types of metabolic effects
we observed here.
In exploring the mechanism(s) underlying the promising
metabolic phenotype of Ad-FLD mice, we discovered that Ad-
FLD mice have an elevation in systemic energy expenditure at
relatively cold ambient temperatures, an effect profoundly sup-
pressed at thermoneutrality. These results indicate that FLD
acts to potentiate adaptive thermogenesis. Probing this pheno-
type revealed that Ad-FLD mice have increased expression of
several thermogenic genes, includingUcp1, and consumemore
oxygen and glucose specifically in the iWAT. These features
combine to suggest that FLD may promote beige/brown con-
version in the subcutaneous WAT. Interestingly, an earlier
study showed that overexpressing full-length Angptl4 in the
WAT and skeletal muscle increases Ucp1 mRNA levels in the
eWAT of mice, although the iWAT was not assessed (33). It is
possible that elevating FLD levels for longer than the 3-week
period in our studywould have also inducedUcp1 expression in
eWAT.Nonetheless, subcutaneousWATdepots such as iWAT
have more abundant beige precursors than do visceral WAT
depots such as eWAT (29, 34), In our experiments, Ucp1
expression and oxygen consumption in the BAT were not aug-
mented by FLD, despite its ability to activate cAMP signaling in
brown adipocytes. This is likely because baseline Ucp1 mRNA
levels and oxygen consumption rates in the BAT are already
quite up-regulated, even in control mice.
We propose that FLD could promote thermogenic energy
expenditure through two potentialmechanisms (Fig. 8). First, it
could do so through the stimulation of cAMP-dependent PKA
activation in adipocytes, leading to downstream transcriptional
induction of thermogenic mediators (26–29) (Fig. 8). Support-
ing this idea, we saw that mRNA levels of Ppargc1a, which is
transcriptionally regulated by cAMP-PKA signaling (30, 35,
36), were elevated in the iWAT of Ad-FLD mice. Induction of
Ppargc1 would, in turn, activate transcription of other ther-
mogenic genes, such as Ucp1 and Cidea. For example, adi-
pocyte-specific knock-out of Ppargc1a reduces Ucp1 expres-
sion and thermogenic capacity in WAT (37). Second, FLD
could increase the availability of intracellular FFAs mobilized
through the cAMP-dependent stimulation of adipocyte lipoly-
sis. These FFAs could then be oxidized bymitochondria to gen-
erate heat and also serve as critical required factors for the stim-
ulation of Ucp1 activity (38, 39). Future work should focus on
determining the relative contribution of these two possibilities
to FLD-induced thermogenesis.
Although lipolysis has been targeted to reduce body weight
(40), unchecked lipolysis can lead to ectopic lipid accumulation
and insulin resistance (41, 42). Indeed, overexpression of full-
length ANGPTL4 was shown to cause hepatic steatosis in mice
(43). How does increased adipocyte lipolysis in Ad-FLD mice
avoid this outcome? One potential explanation is based on
our finding that Ad-FLDmice have suppressed mRNA levels
of genes involved in in fat uptake, synthesis, and storage in
both the liver and skeletal muscle. This down-regulation
may reduce the rate at which FAs fluxing from the WAT to
the liver and muscle are incorporated into TG, thus prevent-
ing steatosis.
Alternatively, FAs in the liver and skeletal muscle could be
consumed through FAO. Although gene expression analysis
did not reveal FLD regulation of genes involved in FAO, FLD
could augment FAO by post-transcriptionally modifying FAO
enzymes and/or molecules involved in mitochondrial respi-
Figure7. IncreasingcirculatingFLD levels in isolation improvesmeasuresofglucosehomeostasis inmice fedaHFD.AandB, lower serumglucose levels
(A) and lower plasma insulin levels (B) versus Ad-LacZ controls during glucose tolerance testing in Ad-FLD mice fed a HFD for 14 days (n 6 mice/group). C,
reduced hepaticmRNA levels of genes encoding the gluconeogenic enzymes PEPCK (Pepck) andG6Pase (G6pc) in Ad-FLDmice fed aHFD for 3weeks (n 5–6
mice/group). *, p 0.05 versus Ad-LacZ in all cases.
ANGPTL4 fibrinogen-like domain and energy expenditure
J. Biol. Chem. (2017) 292(39) 16122–16134 16131
 at U
niversity of California, Berkeley on Septem
ber 29, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ration. Further studies should compare and contrast the rel-
ative roles of FAO, mitochondrial respiration, de novo lipo-
genesis, and TG synthesis on the impact of FLD on hepatic
and muscle TG homeostasis. In any case, what is clear is that
the tissue steatosis produced when full-length Angptl4 is
overexpressed in mice requires the LPL-inhibitory action of
CCD, because increasing systemic FLD levels without con-
comitantly increasing CCD levels prevents, rather than pro-
motes, steatosis.
Overexpressing full-length ANGPTL4 in mice improved
glucose tolerance (43, 44); however, our studies indicate that
overexpressing FLD on its own is sufficient to improve glu-
cose tolerance in mice fed a HFD. As may be true for energy
expenditure, it is possible that FLD improves glucose home-
ostasis through mechanisms other than the enhancement
of WAT lipolysis per se. For example, Ad-FLD mice fed a
HFD had reduced hepatic mRNA levels of gluconeogenic
genes, suggesting that FLD may enhance insulin sensitivity
in the liver and reduce hepatic glucose production. Future
work will need to determine the extent to which FLD direct-
ly regulates hepatic glucose metabolism versus effects
that result indirectly from its regulation of hepatic TG
homeostasis.
We show that Angptl4 exerts metabolic effects through
both its CCD and FLD and that the FLD is specifically
responsible for the ability of Angptl4 to stimulate adipocyte
lipolysis. Moreover, FLD may be more appropriate than
full-length Angptl4 when considering clinical translation,
because FLD can stimulate lipolysis and reduce adiposity
without inducing hypertriglyceridemia. Indeed, increasing
the levels of FLD systemically inmice not only limits DIO but
also improves glucose homeostasis and protects against
hepatic and muscular steatosis. Although this phenotypic
constellation may involve pleiotropic mechanisms, includ-
ing enhanced adipocyte lipolysis, beige/brown conversion,
and the potentiation of adaptive thermogenesis, our study
highlights the potential value of FLD in ameliorating meta-
bolic diseases linked to obesity.
Experimental procedures
Adenovirus production
The adenoviral vector containing full-length human
ANGPTL4 cDNAwas provided by Dr. Ron Kahn (Joslin Diabe-
tes Center, Boston, MA). To generate the FLD vector, the
nucleotide sequence coding amino acids 38–165 of ANGPTL4
was deleted using the QuikChange site-directed mutagenesis
kit (Agilent, Santa Clara, CA). Adenoviruses were produced,
packaged, and amplified by Vector Biolabs (Malvern, PA).
Adenoviruses were injected via tail vein (1 109 pfu/mouse in
PBS).
Mice
All animal experiments were approved by the animal care
and use committee of either the University of California
Berkeley (approval number R306-0111) or the University of
California San Francisco (approval number AN111420-02).
8-week-old male C57BL/6J mice (Charles River, Wilming-
ton, MA) were injected with adenovirus and fed either a
standard low-fat chow diet or a HFD (42% Kcal from fat;
Envigo, Indianapolis, IN) ad libitum for 21 days. The mice
were either housed at 20–22 °C for the entire study or
switched to thermoneutral (30 °C) housing for the last 5
days. Oxygen consumption (VO2), carbon dioxide produc-
tion (VCO2), and RER were monitored in mice by a CLAMS
18 days after adenoviral injection. The data were normalized
to body weight.
Immunoblotting
Tissues were lysed in radioimmune precipitation assay
buffer, and the proteins from lysates were separated by SDS-
PAGE, transferred to nitrocellulose membrane, and probed
with the indicated antibodies. To measure plasma FLAG-FLD
and FLAG-ANGPTL4 levels, 40 l of plasma from Ad-ANG-
PTL4, Ad-FLD, or Ad-LacZ mice was diluted to 1 ml with lysis
buffer and incubated 2 h at 4 °C. Lysates were run through an
anti-FLAGM2 affinity gel (A2220; Sigma) to pull down FLAG-
tagged proteins. The resin was washed with TBS and boiled for
5 min at 100 °C in sample buffer, and the eluent subjected to
SDS-PAGE. Additionally, 3 l of plasma from Ad-FLD or Ad-
LacZmice fed aHFD, alongwith 20.5 ng of purified FLAG-FLD
proteins, were diluted 10-fold in saline, incubated at 95 °C in
sample buffer (31 mM Tris-HCl, pH 6.8, 1% (w/v) glycerol), and
then run on SDS-PAGE. After immunoblotting using FLAG
antibodies (F3165; Sigma; 1:1000 in 5% BSA), ImageJ software
was used to measure the intensity of the resulting bands. The
relative concentration of FLAG-FLD in plasma ofAd-FLDmice
was then calculated.
RNA isolation and quantitative real-time PCR (qPCR)
qPCR was performed as described (45). The primer
sequences are listed (supplemental Table S1).
Figure 8. The model of FLD-induced energy expenditure. FLD acts
through an unidentified receptor to increase intracellular cAMP levels in
adipocytes, which promotes lipolysis. Fatty acids generated from lipolysis
are required for Ucp1 activation. Increasing cAMP levels in adipocytes
could also augment the expression of thermogenic genes, such as
Ppargc1a and Ucp1, which promotes thermogenesis.Dashed lines indicate
multiple steps.
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Plasma TG and FFAmeasurement
Plasma TG levels were measured using a serum triglyceride
determinationkit(TR0100;Sigma).PlasmaFFAlevelsweremea-
sured using a colorimetric kit (MAK044; Sigma).
Body composition analysis
Body composition was analyzed by DEXA with a PIXImus2
scanner (GE Healthcare).
Tissue TGmeasurement
Liver samples were weighed and homogenized in a buffer
containing 50 mM Tris-HCl (pH 7.4) and 250 mM sucrose. Lip-
ids were extracted in chloroform/methanol (2:1) and separated
by TLC on silica gel G-60 plates with the solvent hexane/ethyl
ether/acetic acid (v/v/v, 80:20:1). TheTGbandswere visualized
by exposure to iodine, scraped and analyzed as described (8)
with triolein (T7140; Sigma) as a standard, and expressed per
tissue weight.
Seahorse XF24e analysis
Tissue explants were collected and minced in Krebs–
Henseleit buffer (46). 3–5-mg pieces were transferred to Sea-
horse XF24e islet capture microplates with 500 l of KHB per
well. These microplates were then incubated for 1 h at 37 °C in
absence of CO2, read using an XF24e Analyzer (Seahorse Bio-
science, Billerica,MA), and then homogenized in radioimmune
precipitation assay buffer. OCR and ECAR data were normal-
ized to protein concentration.
Measuring lipolysis from isolated adipocytes
Adipocytes from iWAT were isolated from C57BL/6J mice
and treated with either 20 nMAngptl4, 20 nM FLD, 20 nM E40K,
or buffer as described (8). Glycerol release was measured using
free glycerol reagent (Sigma). cAMP levels were measured by
ELISA (Enzo Life Sciences, Farmingdale, NY). The measure-
ments were normalized to protein concentration (Bio-Rad).
Purification of FLAG-tagged proteins
AD293 cells cultured in DMEM plus 10% FBS and 1% peni-
cillin/streptomycin were infected with adenovirus expressing
FLAG-ANGPTL4, FLAG-FLD, or FLAG-E40K, and FLAG-
tagged proteins were purified as described (8).
Measuring glucose tolerance and plasma insulin levels inmice
The mice were fasted for 6 h and then given i.p. glucose
(1g/kg bodyweight). To perform an intraperitoneal glucose tol-
erance test, tail blood collected at 0, 15, 30, 60, 90, and 120 min
after glucose administrationwas usedmeasure glucose levels by
glucometer (Contour, Bayer). Fasting plasma insulin levels
were measured by an ultra-sensitive mouse insulin ELISA kit
(Crystal Chem, Downers Grove, IL).
Statistical analyses
The data are expressed as means  S.E. Statistically signifi-
cant differences between two groupswere assessed by Student’s
t test. Intraperitoneal glucose tolerance test, CLAMS, and Sea-
horse results were also analyzed by calculating the area under
the curve.
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